Observational studyBMC ophthalmology2025
Progression of diabetic retinopathy in a longitudinal real-world study of patients in primary care.
Observational study in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to assess the impact of diabetic retinopathy (DR) severity on the risk of DR progression to proliferative DR (PDR) or clinically significant macular edema (CSME) in patients with diabetes mellitus (DM).
methodsThis is a prospective, longitudinal, non-interventional, and observational cohort study of patients with DM in the United States based on a database of 7-field color fundus photograph images from primary care visits. Study participants were adults aged ≥ 18 years who underwent DR screening in either eye between January 1999 and December 2016. DR severity was graded according to the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) on 7-field color fundus photographs. The main outcomes were ≥ 2-step DR worsening and development of CSME, PDR, or CSME and PDR together.
resultsFor all 41,977 eyes evaluated, the proportion of eyes with ≥ 2-step DR worsening was 2.7% at year 2 and 9.6% at year 5. Rate of ≥ 2-step DR worsening was greatest among eyes with moderate-to-severe NPDR with baseline DRSS 43-53 (36.5% at year 5). Analysis of PDR and CSME outcomes showed the presence of 3 distinct clinical phenotypes: 1 subset progressed to CSME (1.24% at year 5), another to PDR (0.49% at year 5), and only a small subset progressed to both vision-threatening forms of DR (0.10% at year 5). The clinical phenotype did not appear to be dependent on baseline DRSS.
conclusionsOverall, the risk of progression to vision-threatening forms of DR was more pronounced in eyes with moderate-to-severe non-proliferative DR at baseline. In addition, we found that distinct DR clinical subtypes progressing to either PDR and/or CSME over a 5-year period are not driven by baseline DR severity, suggesting other factors may contribute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.